Covid-19 Research

Open Access
Letter
OCLC

Poly-De-Prescribing to Treat the Iatrogenic Epidemic of Polypharmacy - A Major Public Health Challenge Google Scholar

Read • Cite • Share — permanent Open Access hosting with DOI tracking
Medicine Group
TherapeuticsPharmacologyPublic Health
Article Submission Portal

Garfinkel D

Volume7-Issue1
Dates: Received: 2025-11-21 | Accepted: 2026-01-19 | Published: 2026-01-20
Pages: 1-11

Abstract

FullText HTML FullText PDF DOI: 10.37871/jbres2257

Certificate of Publication

Copyright

© 2026 Garfinkel D. Distributed under Creative Commons CC-BY 4.0

How to cite this article

Garfi nkel D. Poly-De-Prescribing to Treat the Iatrogenic Epidemic of Polypharmacy - A Major Public Health Challenge. J Biomed Res Environ Sci. 2026 Jan 20; 7(1): 11. Doi: 10.37871/jbres2257

Subject area(s)

Therapeutics
Pharmacology
Public Health

References

  1. Garfinkel D. Poly-de-prescribing vs Polypharmacy. The weapon to fight an iatrogenic epidemic: An overview. Eur J Geriatr Gerontol. 2019;1(1):1-10.
  2. Barnett N, Garfinkel D. De-prescribing one year on: challenging the iatrogenic epidemic (Editorial). Eur J Hosp Pharm. 2018; 25:63-64. doi: 10.1136/ejhpharm-2017-001482.
  3. Mangin D, Garfinkel D. Foreword to the first special collection: Addressing the invisible iatrogenic epidemic: the role of deprescribing in polypharmacy and inappropriate medication use. Ther Adv Drug Saf. 2019 Oct 21;10:2042098619883156. doi: 10.1177/2042098619883156. PMID: 31673327; PMCID: PMC6804352.
  4. Garfinkel D, Bilek A. Inappropriate medication use and polypharmacy in older people. BMJ. 2020 Jun 18;369:m2023. doi: 10.1136/bmj.m2023. PMID: 32554409.
  5. Mangin D, Bahat G, Golomb BA, Mallery LH, Moorhouse P, Onder G, Petrovic M, Garfinkel D. International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action. Drugs Aging. 2018 Jul;35(7):575-587. doi: 10.1007/s40266-018-0554-2. PMID: 30006810; PMCID: PMC6061397.
  6. Garfinkel D. Poly-de-prescribing to treat polypharmacy: efficacy and safety. Ther Adv Drug Saf. 2018 Jan;9(1):25-43. doi: 10.1177/2042098617736192. Epub 2017 Oct 27. PMID: 29318004; PMCID: PMC5753993.
  7. Garfinkel D, Levy Y. Optimizing clinical outcomes in polypharmacy through poly-de-prescribing: a longitudinal study. Front Med (Lausanne). 2024 Apr 30;11:1365751. doi: 10.3389/fmed.2024.1365751. PMID: 38745740; PMCID: PMC11091405.
  8. Garfinkel D. Geriatric boom catastrophe - A major medical, economic and social nightmare of the 21st century [Abstract]. Proc 6th. Congress Intern Ass Gerontol Geriatr; 1997. p.364.
  9. Garfinkel D. The tsunami in 21st century healthcare: The age-related vicious circle of co-morbidity-multiple symptoms-over-diagnosis-over treatment-polypharmacy [Abstract]. J Nutr Health & Aging. 2013;17(Suppl. 1):SS24-227-C-1.
  10. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005 Aug 10;294(6):716-24. doi: 10.1001/jama.294.6.716. PMID: 16091574.
  11. Stavert RR, Lott JP. The bystander effect in medical care. N Engl J Med. 2013 Jan 3;368(1):8-9. doi: 10.1056/NEJMp1210501. PMID: 23281972.
  12. Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications to combat polypharmacy. Ther Adv Drug Saf. 2015 Dec;6(6):212-33. doi: 10.1177/2042098615613984. PMID: 26668713; PMCID: PMC4667766.
  13. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997 Oct 25;315(7115):1096-9. doi: 10.1136/bmj.315.7115.1096. PMID: 9366745; PMCID: PMC2127690.
  14. Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A, Shulman KI, Lee PE, Rochon PA. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005 Apr 11;165(7):808-13. doi: 10.1001/archinte.165.7.808. PMID: 15824303.
  15. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007 Jul 14;370(9582):173-184. doi: 10.1016/S0140-6736(07)61091-5. PMID: 17630041.
  16. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001 Mar-Apr;41(2):192-9. doi: 10.1016/s1086-5802(16)31229-3. PMID: 11297331.
  17. Hoonhout LH, de Bruijne MC, Wagner C, Zegers M, Waaijman R, Spreeuwenberg P, Asscheman H, van der Wal G, van Tulder MW. Direct medical costs of adverse events in Dutch hospitals. BMC Health Serv Res. 2009 Feb 9;9:27. doi: 10.1186/1472-6963-9-27. PMID: 19203365; PMCID: PMC2645386.
  18. Stark RG, John J, Leidl R. Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach. BMC Health Serv Res. 2011 Jan 13;11:9. doi: 10.1186/1472-6963-11-9. PMID: 21232111; PMCID: PMC3032652.
  19. Rottenkolber D, Hasford J, Stausberg J. Costs of adverse drug events in German hospitals--a microcosting study. Value Health. 2012 Sep-Oct;15(6):868-75. doi: 10.1016/j.jval.2012.05.007. Epub 2012 Aug 9. PMID: 22999137.
  20. Santibáñez-Beltrán S, Villarreal-Ríos E, Galicia-Rodríguez L, Martínez-González L, Vargas-Daza ER, Ramos-López JM. Costo económico de la polifarmacia en el adulto mayor en el primer nivel de atención [Economic cost of polypharmacy in the elderly in primary health care]. Rev Med Inst Mex Seguro Soc. 2013 Mar-Apr;51(2):192-9. Spanish. PMID: 23693109.
  21. Hovstadius B, Petersson G. The impact of increasing polypharmacy on prescribed drug expenditure-a register-based study in Sweden 2005-2009. Health Policy. 2013 Feb;109(2):166-74. doi: 10.1016/j.healthpol.2012.09.005. Epub 2012 Nov 26. PMID: 23195435.
  22. Gnjidic D, Le Couteur DG, Pearson SA, McLachlan AJ, Viney R, Hilmer SN, Blyth FM, Joshy G, Banks E. High risk prescribing in older adults: prevalence, clinical and economic implications and potential for intervention at the population level. BMC Public Health. 2013 Feb 7;13:115. doi: 10.1186/1471-2458-13-115. PMID: 23388494; PMCID: PMC3570486.
  23. Kwak MJ, Chang M, Chiadika S, Aguilar D, Avritscher E, Deshmukh A, Goyal P, Kim DH, Aparasu R, Holmes HM. Healthcare Expenditure Associated With Polypharmacy in Older Adults With Cardiovascular Diseases. Am J Cardiol. 2022 Apr 15;169:156-158. doi: 10.1016/j.amjcard.2022.01.012. Epub 2022 Feb 12. PMID: 35168755; PMCID: PMC9313779.
  24. Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J. 2007 Jun;9(6):430-4. PMID: 17642388.
  25. Garfinkel D, Ilin N, Waller A, Torkan-Zilberstein A, Zilberstein N, Gueta I. Inappropriate medication use and polypharmacy in end-stage cancer patients: Isn't it the family doctor's role to de-prescribe much earlier? Int J Clin Pract. 2018 Apr;72(4):e13061. doi: 10.1111/ijcp.13061. Epub 2018 Jan 23. PMID: 29359381.
  26. Kotlinska-Lemieszek A, Paulsen O, Kaasa S, Klepstad P. Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients. J Pain Symptom Manage. 2014 Dec;48(6):1145-59. doi: 10.1016/j.jpainsymman.2014.03.008. Epub 2014 Apr 26. PMID: 24780183.
  27. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990 Apr;150(4):841-5. PMID: 2327844.
  28. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015 Nov;63(11):2227-46. doi: 10.1111/jgs.13702. Epub 2015 Oct 8. PMID: 26446832.
  29. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015 Mar;44(2):213-8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16. Erratum in: Age Ageing. 2018 May 1;47(3):489. doi: 10.1093/ageing/afx178. PMID: 25324330; PMCID: PMC4339726.
  30. Pazan F, Weiss C, Wehling M; FORTA Expert Panel Members. The EURO-FORTA (Fit fOR The Aged) List Version 2: Consensus Validation of a Clinical Tool for Improved Pharmacotherapy in Older Adults. Drugs Aging. 2023 May;40(5):417-426. doi: 10.1007/s40266-023-01024-6. Epub 2023 May 2. PMID: 37129833; PMCID: PMC10152014.
  31. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010 Oct 11;170(18):1648-54. doi: 10.1001/archinternmed.2010.355. PMID: 20937924.
  32. Steinman MA, Rosenthal GE, Landefeld CS, Bertenthal D, Kaboli PJ. Agreement between drugs-to-avoid criteria and expert assessments of problematic prescribing. Arch Intern Med. 2009 Jul 27;169(14):1326-32. doi: 10.1001/archinternmed.2009.206. PMID: 19636035; PMCID: PMC2758269.
  33. Rieckert A, Reeves D, Altiner A, Drewelow E, Esmail A, Flamm M, Hann M, Johansson T, Klaassen-Mielke R, Kunnamo I, Löffler C, Piccoliori G, Sommerauer C, Trampisch US, Vögele A, Woodham A, Sönnichsen A. Use of an electronic decision support tool to reduce polypharmacy in elderly people with chronic diseases: cluster randomised controlled trial. BMJ. 2020 Jun 18;369:m1822. doi: 10.1136/bmj.m1822. PMID: 32554566; PMCID: PMC7301164.
  34. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006 Mar 27;166(6):605-9. doi: 10.1001/archinte.166.6.605. PMID: 16567597.
  35. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013 Oct;30(10):793-807. doi: 10.1007/s40266-013-0106-8. PMID: 23912674.
  36. Scott IA, Anderson K, Freeman C. Evidence-based deprescribing: Reversing the tide of potentially inappropriate polypharmacy. J Clin Outcomes Management. 2016;23(8):359-69.
  37. Campins L, Serra-Prat M, Gózalo I, López D, Palomera E, Agustí C, Cabré M; REMEI Group. Randomized controlled trial of an intervention to improve drug appropriateness in community-dwelling polymedicated elderly people. Fam Pract. 2017 Feb;34(1):36-42. doi: 10.1093/fampra/cmw073. Epub 2016 Sep 7. PMID: 27605543.
  38. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996 Jan 13;312(7023):71-2. doi: 10.1136/bmj.312.7023.71. PMID: 8555924; PMCID: PMC2349778.
  39. Mallery LH, Ransom T, Steeves B, Cook B, Dunbar P, Moorhouse P. Evidence-informed guidelines for treating frail older adults with type 2 diabetes: from the Diabetes Care Program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) program. J Am Med Dir Assoc. 2013 Nov;14(11):801-8. doi: 10.1016/j.jamda.2013.08.002. Epub 2013 Sep 24. PMID: 24074961.
  40. Mallery LH, Allen M, Fleming I, Kelly K, Bowles S, Duncan J, Moorhouse P. Promoting higher blood pressure targets for frail older adults: a consensus guideline from Canada. Cleve Clin J Med. 2014 Jul;81(7):427-37. doi: 10.3949/ccjm.81a.13110. PMID: 24987044.
  41. Todd A, Holmes H, Pearson S, Hughes C, Andrew I, Baker L, Husband A. 'I don't think I'd be frightened if the statins went': a phenomenological qualitative study exploring medicines use in palliative care patients, carers and healthcare professionals. BMC Palliat Care. 2016 Jan 29;15:13. doi: 10.1186/s12904-016-0086-7. PMID: 26822776; PMCID: PMC4731932.
  42. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, McLachlan AJ, Cumming RG, Handelsman DJ, Le Couteur DG. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012 Sep;65(9):989-95. doi: 10.1016/j.jclinepi.2012.02.018. Epub 2012 Jun 27. PMID: 22742913.
  43. Woodward MC. Deprescribing: Achieving better health outcomes for older people through reducing medications. J Pharm Pract Res. 2003;33:323-8. doi: 10.1002/jppr2003334323.
  44. Farrell B, Mangin D. Deprescribing Is an Essential Part of Good Prescribing. Am Fam Physician. 2019 Jan 1;99(1):7-9. PMID: 30600973.
  45. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013 Oct;30(10):793-807. doi: 10.1007/s40266-013-0106-8. PMID: 23912674.
  46. Reeve E, Wolff JL, Skehan M, Bayliss EA, Hilmer SN, Boyd CM. Assessment of Attitudes Toward Deprescribing in Older Medicare Beneficiaries in the United States. JAMA Intern Med. 2018 Dec 1;178(12):1673-1680. doi: 10.1001/jamainternmed.2018.4720.
  47. Bilek AJ, Levy Y, Kab H, Andreev P, Garfinkel D. Teaching physicians the GPGP method promotes deprescribing in both inpatient and outpatient settings. Ther Adv Drug Saf. 2019 Dec 27;10:2042098619895914. doi: 10.1177/2042098619895914. PMID: 31908757; PMCID: PMC6935879.
  48. Turner JP, Currie J, Trimble J, Tannenbaum C. Strategies to promote public engagement around deprescribing. Ther Adv Drug Saf. 2018 Sep 12;9(11):653-665. doi: 10.1177/2042098618794165. PMID: 30479740; PMCID: PMC6243424.
  49. Scott IA, Anderson K, Freeman CR, Stowasser DA. First do no harm: a real need to deprescribe in older patients. Med J Aust. 2014 Oct 6;201(7):390-2. doi: 10.5694/mja14.00146. PMID: 25296059.
  50. Linsky A, Simon SR, Bokhour B. Patient perceptions of proactive medication discontinuation. Patient Educ Couns. 2015 Feb;98(2):220-5. doi: 10.1016/j.pec.2014.11.010. Epub 2014 Nov 20. PMID: 25435516.
  51. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014 Oct;78(4):738-47. doi: 10.1111/bcp.12386. PMID: 24661192; PMCID: PMC4239968.
  52. McCahon D, Duncan P, Payne R, Horwood J. Patient perceptions and experiences of medication review: qualitative study in general practice. BMC Prim Care. 2022 Nov 22;23(1):293. doi: 10.1186/s12875-022-01903-8. PMID: 36418986; PMCID: PMC9682692.

Comments

Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership